Elsevier

The Lancet

Volume 359, Issue 9310, 16 March 2002, Pages 943-945
The Lancet

Research Letters
Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma

https://doi.org/10.1016/S0140-6736(02)07990-4Get rights and content

Summary

Increased expression of survivin has been shown to be a negative predictor of survival in patients with soft-tissue sarcoma. We investigated 89 adults with soft-tissue sarcomas to ascertain the relation between co-expression of survivin and human telomerase reverse transcriptase (TERT) transcripts and prognosis. We quantified mRNA expression of survivin and TERT transcripts. Cox's proportional-hazards regression model showed co-expression of both genes to be a significant negative prognostic factor for patients with stage I to stage IV tumours (p=0·0004; relative risk 20·1, 95% CI 3·8-106·4) and for those at stage II and III (p=0·0002; 42·1, 6·0–294·9) compared with low expression of both genes. Co-expression of survivin and TERT transcripts identifies patients at high risk of tumour-related death.

References (5)

There are more references available in the full text version of this article.

Cited by (82)

  • The Multiple Roles of the IAP Super-family in cancer

    2020, Pharmacology and Therapeutics
    Citation Excerpt :

    hTERT maintains telomeres and prevents telomere shortening, which normally happens during each cell division,. . A number of reports have correlated Survivin expression with hTERT expression in tumor tissues (Kleinschmidt-DeMasters et al., 2003; Lam, Saleh, Smith, & Ho, 2008; Wellenhofer & Brustmann, 2012; Würl et al., 2002). Moreover, recent reports have shown that Survivin also regulates telomerase activity.

  • High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth

    2017, Translational Oncology
    Citation Excerpt :

    Normally, survivin is expressed during fetal development and also in certain differentiated tissues. High expression of survivin has been found in several malignancies, including sarcomas such as malignant peripheral nerve sheath tumor, pleomorphic liposarcoma, uterine leiomyosarcoma, chondrosarcoma, and Ewing sarcoma [20,39–43]. All primary MLS tumor samples, as well as the three cell lines, showed high nuclear expression of survivin.

  • Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients

    2012, International Journal of Radiation Oncology Biology Physics
    Citation Excerpt :

    Survivin is expressed at a high level in many common human cancers but not in normal, terminally differentiated, adult tissues (30, 33). In previous studies the expression of survivin has been evaluated in malignant tissue samples from 63 STS patients as well as from a panel of tumor cell lines (34, 35). High survivin levels were detected in tumor samples from more than 75% of patients with Stage II and from more than 90% patients with Stage III STS (35).

  • Grading sarcomas: Histologic and molecular approaches

    2011, Diagnostic Histopathology
    Citation Excerpt :

    Allowing for these simple rules only few molecular markers could be recognized as prognostic in sarcomas. The history of molecular prognostic markers in sarcomas started in the beginning of the 2000’s, with the study reported by Würl et al.15 The authors showed that expression of two genes TERT (telomerase reverse transcriptase) and survivin (also named BIRC5) is associated to poor outcome in a series of 89 sarcomas of different subtypes. This series was composed of sarcomas with complex genetics such as leiomyosarcomas, pleomorphic rhabdomyosarcomas and pleomorphic liposarcomas, and in these tumours, co-expression of both genes was a significant prognostic factor (P = 0.0004; relative risk 20.1, 95% CI 3.8–106.4).

View all citing articles on Scopus
View full text